Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Salvage surgery and reirradiation for locoregional recurrence
10 evidence topics · 10 sources
Recurrent oral cavity cancer: surgery and radiation therapy by initial treatment
Recurrent laryngeal cancer: salvage surgery and reirradiation
Recurrent oropharyngeal cancer: surgical resection and additional radiation therapy
International consensus on reirradiation
“Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Radiation therapy combined with immunotherapy for locoregional recurrence or oligometastatic disease
Salvage surgery versus nonsurgical management: meta-analysis
“Fifteen studies reported survival for salvage surgery and nonsurgical management of recurrence. Five-year OS ranged from 26% to 67% for the salvage surgery groups, compared to 0% to 32% for the nonsurgical management groups. Six studies reported HRs comparing salvage surgery to nonsurgical management; the pooled HR was 0.25 (95% CI [0.16, 0.38]; p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Salvage surgery and survival after progression of oropharyngeal cancer
Reirradiation with intensity-modulated radiotherapy: meta-analysis
“A total of 17 studies involving 1635 patients were included. Fourteen (82%) of those were retrospective, and 15 (88%) were from single institution. Reirradiation with IMRT produced pooled 2-year LC and OS rates of 52% (95% confidence interval [CI], 46%-57%) and 46% (95% CI, 41%-50%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled rates of late grade ≥ 3 and grade 5 toxicities were 26% (95% CI, 20%-32%) and 3.1% (95% CI, 2%-5%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Postoperative reirradiation with chemotherapy after salvage surgery: randomized trial
“Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 2 years, 39% of patients in the RT arm and 10% in the WS arm experienced grade 3 or 4 late toxicity according to Radiation Therapy Oncology Group criteria (P = .06).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Full-dose reirradiation combined with chemotherapy after salvage surgery significantly improved DFS, but had no significant impact on OS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Palliative reirradiation with chemotherapy versus methotrexate: randomized trial
“Due to a very slow accrual, the trial was closed after inclusion of 57 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“re-irradiation did not improve OS compared with methotrexate (23% versus 22% at 1year, NS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote